SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-035716
Filing Date
2023-10-05
Accepted
2023-10-04 21:05:13
Documents
13
Period of Report
2023-10-04
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 38472
  Complete submission text file 0001493152-23-035716.txt   251685

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE lixt-20231004.xsd EX-101.SCH 3519
3 XBRL DEFINITION FILE lixt-20231004_def.xml EX-101.DEF 26564
4 XBRL LABEL FILE lixt-20231004_lab.xml EX-101.LAB 36548
5 XBRL PRESENTATION FILE lixt-20231004_pre.xml EX-101.PRE 25188
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 4915
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

IRS No.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 231309655
SIC: 2834 Pharmaceutical Preparations